Abstract
The possibilities of adjuvant therapy of malignant melanoma have significantly expanded in recent years. The article presents the failure of adjuvant nivolumab immunotherapy in a patient with locally advanced stage IIIC malignant melanoma.
Ipilimumab has been selected as a treatment choice and demostrated its efficacy. However, its administration was associated with immune-related side effects.
Although adjuvant theapy has significantly reduced a risk of disease relapse, there is a cohort of patients in whom adjuvant therapy fails. Failure may occur after the end of the therapy or, as i our case, during the therapy.
Based on currently available data, it is not possible unambiguously choose the optimal procedure after adjuvant therapy failure.